Company profile
Superluminal Medicines
Biotechnology company combining AI/ML, protein dynamics and structural biology to design small-molecule medicines against G protein-coupled receptor targets. Proceeds from the oversubscribed Series B will fund a Phase 1 trial of its lead MC4R agonist in rare genetic and hypothalamic obesity, expected to begin by the end of 2026.
- Location
- Boston, MA
- Website
- superluminalrx.com
Latest known funding
Series B round
- Capital
- $60M
- Announced
- Sep 3, 2026